CN105307675A - 使用抗il23抗体治疗克罗恩氏病的方法 - Google Patents

使用抗il23抗体治疗克罗恩氏病的方法 Download PDF

Info

Publication number
CN105307675A
CN105307675A CN201480015713.3A CN201480015713A CN105307675A CN 105307675 A CN105307675 A CN 105307675A CN 201480015713 A CN201480015713 A CN 201480015713A CN 105307675 A CN105307675 A CN 105307675A
Authority
CN
China
Prior art keywords
antibody
day
disease
antibodies
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480015713.3A
Other languages
English (en)
Chinese (zh)
Inventor
W.潘
W.楚吉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CN105307675A publication Critical patent/CN105307675A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
CN201480015713.3A 2013-03-15 2014-02-25 使用抗il23抗体治疗克罗恩氏病的方法 Pending CN105307675A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361789976P 2013-03-15 2013-03-15
US61/789976 2013-03-15
PCT/US2014/018308 WO2014143540A1 (en) 2013-03-15 2014-02-25 Methods for treating crohn's disease using an anti-il23 antibody

Publications (1)

Publication Number Publication Date
CN105307675A true CN105307675A (zh) 2016-02-03

Family

ID=50236361

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480015713.3A Pending CN105307675A (zh) 2013-03-15 2014-02-25 使用抗il23抗体治疗克罗恩氏病的方法

Country Status (17)

Country Link
US (5) US20160031983A1 (xx)
EP (2) EP2968486A1 (xx)
JP (4) JP2016516686A (xx)
KR (1) KR20150128859A (xx)
CN (1) CN105307675A (xx)
AP (1) AP2015008801A0 (xx)
AU (1) AU2014228553B2 (xx)
CA (1) CA2906384A1 (xx)
CL (1) CL2015002724A1 (xx)
EA (1) EA201591579A1 (xx)
HK (1) HK1220605A1 (xx)
IL (2) IL241343A0 (xx)
NZ (1) NZ712294A (xx)
PH (1) PH12015502133A1 (xx)
SG (2) SG10201805015TA (xx)
TN (1) TN2015000402A1 (xx)
WO (1) WO2014143540A1 (xx)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109071653A (zh) * 2016-03-29 2018-12-21 詹森生物科技公司 用增加的抗-il12和/或-23抗体给药间隔治疗牛皮癣
CN111956606A (zh) * 2020-08-31 2020-11-20 江苏荃信生物医药有限公司 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂
CN114641493A (zh) * 2019-08-21 2022-06-17 阿斯特捷利康合作创业有限责任公司 使用布雷库单抗治疗克罗恩病

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
JP6126532B2 (ja) 2010-11-04 2017-05-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−２３抗体
MX368653B (es) 2012-05-03 2019-10-10 Boehringer Ingelheim Int Anticuerpos anti-il-23p19.
US10507241B2 (en) 2014-07-24 2019-12-17 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of IL-23A related diseases
TWI711629B (zh) 2014-09-03 2020-12-01 德商包林格因蓋爾漢國際股份有限公司 靶向IL-23A與TNF-α之化合物及其用途
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
JP2018507868A (ja) * 2015-02-26 2018-03-22 ジェネンテック， インコーポレイテッド インテグリンベータ７アンタゴニスト及びクローン病の治療方法
TWI733695B (zh) * 2015-09-18 2021-07-21 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
EP3848390A1 (en) * 2016-10-14 2021-07-14 Boehringer Ingelheim International GmbH Methods of treating diseases
US20210277105A1 (en) * 2018-07-13 2021-09-09 Astrazeneca Collaboration Ventures, Llc Treating ulcerative colitis with brazikumab
TW202103734A (zh) 2019-04-22 2021-02-01 美商美國禮來大藥廠 治療克隆氏症（ｃｒｏｈｎ＇ｓ ｄｉｓｅａｓｅ）的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011056600A1 (en) * 2009-10-26 2011-05-12 Amgen Inc. Human il-23 antigen binding proteins

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
PE20000183A1 (es) 1997-07-25 2000-03-11 Schering Corp Citoquinas de mamiferos y reactivos relacionados
EP3501537A1 (en) 2005-06-30 2019-06-26 Janssen Biotech, Inc. Anti-il23 antibodies, compositions, methods and uses
WO2007024846A2 (en) 2005-08-25 2007-03-01 Eli Lilly And Company Anit-il-23 antibiodies
US20070050011A1 (en) 2005-08-26 2007-03-01 Medlogics Device Corporation Lumen-supporting stents and methods for creating lumen-supporting stents with various open/closed designs
EP2354160A1 (en) 2005-08-31 2011-08-10 Schering Corporation Engineered anti-IL-23-antibodies
US7686047B2 (en) * 2005-11-04 2010-03-30 Roger Cleveland Golf Co., Inc. Golf club cover
PL1971366T3 (pl) 2005-12-29 2015-01-30 Janssen Biotech Inc Ludzkie przeciwciała skierowane przeciw IL-23, kompozycje, sposoby i zastosowanie
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
BRPI0807710B1 (pt) 2007-02-23 2021-12-14 Merck Sharp & Dohme Corp Anticorpos que se ligam a il-23p19 e il-23 humana, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira microbiana, método de produção de um polipeptídeo e composição farmacêutica
SG178804A1 (en) 2007-02-23 2012-03-29 Schering Corp Engineered anti-il-23p19 antibodies
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
US20090117289A1 (en) * 2007-10-09 2009-05-07 Enerize Corporation Method and apparatus for deposition of thin film materials for energy storage devices
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
EP2274333A4 (en) * 2008-03-18 2011-06-15 Abbott Lab PROCESS FOR TREATING PSORIASIS
JP5931442B2 (ja) 2008-08-27 2016-06-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 操作された抗ＩＬ−２３ｐ１９抗体の凍結乾燥製剤
CA2757237A1 (en) 2009-04-01 2010-10-14 Jane Elizabeth Clarkson Anti-il-23 immunoglobulins
EP2435480A1 (en) * 2009-05-27 2012-04-04 Ablynx N.V. Biparatopic protein constructs directed against il-23
EA201891433A3 (ru) 2010-01-15 2019-02-28 Кирин-Эмджен, Инк. Состав антитела и терапевтические режимы
CA2805653A1 (en) 2010-07-20 2012-01-26 Cephalon Australia Pty Ltd Anti-il-23 heterodimer specific antibodies
US9717791B2 (en) * 2010-10-08 2017-08-01 Novartis Ag Methods of treating psoriasis using IL-17 antibody
JP6126532B2 (ja) 2010-11-04 2017-05-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−２３抗体
TW201242976A (en) * 2011-01-07 2012-11-01 Abbott Lab Anti-IL-12/IL-23 antibodies and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011056600A1 (en) * 2009-10-26 2011-05-12 Amgen Inc. Human il-23 antigen binding proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DUVALLET EMILIE ET AL: "Interleukin-23:A key cytokine in inflammatory diseases", 《ANNALS OF MEDICINE》 *
MARKUS F NEURATH ET AL: "IL-23:a master regulator in Crohn disease", 《NATURE MEDICINE》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109071653A (zh) * 2016-03-29 2018-12-21 詹森生物科技公司 用增加的抗-il12和/或-23抗体给药间隔治疗牛皮癣
CN114641493A (zh) * 2019-08-21 2022-06-17 阿斯特捷利康合作创业有限责任公司 使用布雷库单抗治疗克罗恩病
CN111956606A (zh) * 2020-08-31 2020-11-20 江苏荃信生物医药有限公司 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂
CN111956606B (zh) * 2020-08-31 2021-05-14 江苏荃信生物医药有限公司 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂

Also Published As

Publication number Publication date
IL241343A0 (en) 2015-11-30
SG11201507483PA (en) 2015-10-29
NZ712294A (en) 2020-04-24
TN2015000402A1 (fr) 2017-01-03
JP2016516686A (ja) 2016-06-09
SG10201805015TA (en) 2018-07-30
WO2014143540A1 (en) 2014-09-18
IL275092A (en) 2020-07-30
EP2968486A1 (en) 2016-01-20
KR20150128859A (ko) 2015-11-18
EP3693007A1 (en) 2020-08-12
CA2906384A1 (en) 2014-09-18
PH12015502133A1 (en) 2016-01-25
JP2023012516A (ja) 2023-01-25
AP2015008801A0 (en) 2015-10-31
US20200017581A1 (en) 2020-01-16
AU2014228553B2 (en) 2019-01-24
AU2014228553A1 (en) 2015-10-08
HK1220605A1 (zh) 2017-05-12
US20160031983A1 (en) 2016-02-04
US20170218062A1 (en) 2017-08-03
US20200283517A1 (en) 2020-09-10
JP2021107397A (ja) 2021-07-29
CL2015002724A1 (es) 2016-03-28
EA201591579A1 (ru) 2016-01-29
US20180327490A1 (en) 2018-11-15
JP2020073470A (ja) 2020-05-14

Similar Documents

Publication Publication Date Title
CN105307675A (zh) 使用抗il23抗体治疗克罗恩氏病的方法
US20230058395A1 (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
US20220135668A1 (en) Methods for Treating Psoriasis Using an Anti-IL-23 Antibody
US20230122171A1 (en) Use of Brazikumab to Treat Crohn's Disease
US20210277105A1 (en) Treating ulcerative colitis with brazikumab
TW202041536A (zh) 藉由投與il-4r拮抗劑治療異位性皮膚炎的方法
CN118286417A (en) Methods of treating atopic dermatitis with IL-4R antagonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1220605

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160203

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1220605

Country of ref document: HK